News > Reasons young women stop taking tamoxifen vary over time

Reasons young women stop taking tamoxifen vary over time

general_content

Looking at a little understood yet common phenomenon—women discontinuing tamoxifen therapy early—French researchers found several factors caused women to interrupt treatment. These factors varied, depending upon when the women stopped therapy.

The study was published in the Annals of Oncology.

Background and reason for the study

Tamoxifen is a medicine used to treat hormone receptor-positive breast cancer, often in premenopausal women. It is given after primary treatments such as surgery and chemotherapy.

Tamoxifen prevents the return of breast cancer by blocking estrogen from reaching estrogen receptors. The standard recommendation is to take tamoxifen for five years, although a major new study now suggests that giving it for 10 years increases benefits.

Although tamoxifen is effective, many women stop taking it before they finish the full treatment course. Some may stop because of common side effects, such as hot flashes, vaginal dryness and mood swings. Others may worry about tamoxifen’s rare side effects, including blood clots and increased risk of uterine cancer. Some women might stop in order to become pregnant, since tamoxifen can damage a fetus.

Other factors also might cause women to stop treatment. The researchers wanted to find out how often young women discontinue tamoxifen and to identify the reasons why.

Study structure

The study looked at 196 women from southeastern France who were 18 to 40 years old at diagnosis. The women, diagnosed from 2005 to 2008, were part of a larger group being studied to learn about their post-treatment lives.

Using pharmacy refill data, the researchers measured how often women stopped tamoxifen treatment. An interruption was defined as two or more consecutive months without dispensed tamoxifen prescriptions.

To determine when the women discontinued tamoxifen, the researchers looked at two time periods:

  • From the start of taking tamoxifen to 16 months after diagnosis
  • From 16 months to 28 months post-diagnosis

Reasons for stopping tamoxifen were organized according to the treatment time period.

Findings

Within the first two years of treatment, 42 percent of the young women stopped taking tamoxifen.

In the first time period (up to 16 months after diagnosis), interruptions were associated with:

  • Lack of information the women could understand about tamoxifen
  • Not enough social support

For the second time period (16 to 28 months after diagnosis), interruptions were associated with:

  • Side effects
  • No longer being afraid of breast cancer returning
  • Lack of social support
  • Not being able to ask questions at diagnosis
  • Fewer types of treatment

The researchers concluded that better communications between women and providers and improved information might help prevent discontinuation of tamoxifen. They also advised healthcare providers to give more attention to women who have little social support.

What this means for you

It can be difficult to think about taking a medicine every day for five or 10 years, especially if you have side effects. Yet tamoxifen can be a key part of your continuing care and staying on it helps prevent a breast cancer recurrence.

If you are having trouble taking tamoxifen, or are thinking about stopping for any reason, talk with your healthcare team before discontinuing. They can offer ways to lessen or eliminate side effects. They also understand the emotional concerns you may be facing.

Your oncologist can answer questions you may have about using tamoxifen or wanting to become pregnant. Your oncology nurse may have suggestions for dealing with side effects and ways to stay on medicine important for avoiding a breast cancer return. You might also find it helpful to talk with an oncology social worker or counselor.

C Cluze, D Rey, L Huiart et al. Adjuvant Endocrine Therapy with Tamoxifen in Young Women with Breast Cancer: Determinants of Interruptions Vary Over TimeAnnals of Oncology, 2012; 23(4):882-890.

disclaimer_box

This article was supported by Cooperative Agreement Number DP11-1111 from The Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.

related_resources_article_carousel

Related resources

Related articles and posts

Early menopause

08/26/22 | BY: Ann Honebrink

If you are premenopausal or perimenopausal, breast cancer treatments — including surgery to remove ovaries, chemotherapy, and hormonal therapy — may cause your menstrual periods to stop for a while or, in some cases, permanently.

Read More | 9 Min. Read |

Young Women

05/04/22 | BY: Don S. Dizon

If you’re a woman diagnosed with breast cancer before the age of 45, your medical and emotional concerns may be very different than those of women who are diagnosed when they are older. Body image, relationships, career, intimacy, fertility, and parenting are just some of the issues and life areas that can bring up questions for you.

Read More |

Ovarian suppression

11/05/19

Ovarian suppression is surgery, radiation therapy or medicine that is used in premenopausal women to stop the ovaries from working.

Read More | 4 Min. Read

Types of hormonal therapy

11/04/19 | BY: Jennifer Winn

Hormonal therapy medicines are put into classes based on how they interact with the body’s natural hormones estrogen and progesterone. Some stop the body from making estrogen, while others prevent estrogen from helping the cancer cell grow.

Read More | 6 Min. Read

Tamoxifen

11/04/19 | BY: Jennifer Winn

Tamoxifen is a type of hormonal therapy called a SERM, or selective estrogen receptor modulator, a medicine that prevents estrogen signals from getting to breast cancer cells.

Read More | 6 Min. Read

Gonadotropin releasing hormone (GnRH) agonists

10/07/19 | BY: H. Irene Su

The gonadotropin releasing hormone agonists, or GnRH agonists, are a class of injectable medicines offered to pre- and perimenopausal women with breast cancer in order to temporarily suppress, or slow, ovarian function.

Read More | 5 Min. Read

Making decisions about protecting your fertility

09/06/19 | BY: H. Irene Su

You might not be thinking about having a family at the time of your diagnosis, but that’s the best time to talk with your partner, family, and healthcare team about future fertility.

Read More | 6 Min. Read

Protecting your fertility during treatment

08/06/19 | BY: H. Irene Su

If you are premenopausal (still having menstrual periods), breast cancer treatments such as chemotherapy and hormonal therapy can affect your fertility. This may make it harder to become pregnant after treatment ends.

Read More | 6 Min. Read

Birth control and breast cancer

08/05/19 | BY: H. Irene Su

If you were not in menopause before your breast cancer diagnosis and you are sexually active, it’s important to discuss birth control, or contraception, with your doctor. During treatment, you should not become pregnant. Early in pregnancy, chemotherapy and hormonal therapy can harm a fetus and lead to birth defects.

Read More | 5 Min. Read

Am I in menopause

08/05/19 | BY: H. Irene Su

Women affected by breast cancer may be premenopausal or perimenopausal before diagnosis. Learn more about early menopause, and other ways that you may be affected.

Read More | 5 Min. Read
3_callout_columns